BioSpace News Archive

Adaptive Biotechnologies Corporation announced it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2022 and business highlights.

Senti Bio, a leading gene circuit company, today announced the acceptance of four abstracts for presentation at upcoming scientific conferences.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2022 financial results and operational highlights on Monday, May 9, 2022, following the close of U.S. financial markets.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), today announced 510k clearance for use of the KORU Medical FreedomEdge® infusion system to deliver pegcetacoplan 20 mL solution, branded as EMPAVELI® or Aspaveli® and commercialized by Apellis in the United States and by Sobi outside the United States.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update.

Ambrx Biopharma Inc., or Ambrx announced that it filed its annual report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission on April 26, 2022.

Veracyte, Inc. (Nasdaq: VCYT) announced today that an updated clinical practice guideline highlights the role of the Envisia Genomic Classifier in the diagnosis of idiopathic pulmonary fibrosis (IPF).

Genenta Science announces that preliminary findings from its Phase 1/2a of Temferon™ in the treatment of patients with glioblastoma multiforme patients who have an unmethylated MGMT gene promoter provide initial evidence of Temferon’s potential for modulating the tumor microenvironment as well as details of Temferon’s continuing positive safety profile and signals of biological activity.

Cabaletta Bio, Inc. announced that data from its two lead programs, DSG3-CAART and MuSK-CAART, will be presented at multiple upcoming scientific meetings in May 2022.